BeOne Medicines AG ONC
395.95 USD -3.75 (-0.94%)
As ofNov 20, 2026, 12:28 PM EST
385.00 Day range 399.76
253.95 52-week range 424.73
- YTD
- +30.33%
- 1 year
- +13.36%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 470.52 +18.8% upside
Now 395.95
- Target (low)
- 412.00
- Target (mean)
- 470.52
- Target (high)
- 561.30
Ratings (0m) 27 26 buy · 1 hold · 0 sell
- Strong buy7
- Buy19
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 27
- 1 month ago 27
- 2 months ago 28
- 3 months ago 28
Included in Essentials and up
Sign in to see Revenue and earnings forecast
Reported revenue and earnings per share by year, then what analysts expect next.
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.65 | 1.85 – 3.60 | 0.58 | +356.1% | 1.88B | +25.6% | 10 |
| Next quarter | 2.13 | 1.52 – 2.80 | 1.96 | +8.5% | 1.76B | +16.6% | 5 |
| Current year | 9.89 | 8.16 – 10.92 | 2.53 | +290.7% | 6.92B | +29.5% | 14 |
| Next year | 10.78 | 5.83 – 15.24 | 9.89 | +9.1% | 7.95B | +14.9% | 17 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 6, 2026 | Truist Securities | Reiterated | Buy | Buy |
| Nov 6, 2026 | Barclays | Maintained | Overweight | Overweight |
| Nov 6, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Nov 6, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Oct 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 7, 2026 | Truist Securities | Maintained | Buy | Buy |
| Oct 1, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 10, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 6, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 6, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 6, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 6, 2026 | Barclays | Maintained | Overweight | Overweight |
| Aug 6, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Jul 23, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 14, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 13, 2026 | Jefferies | Upgrade | Hold | Buy |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 7, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jul 1, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Jun 2, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 15, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| May 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| May 7, 2026 | Guggenheim | Maintained | Buy | Buy |
| May 7, 2026 | Truist Securities | Reiterated | Buy | Buy |
| May 4, 2026 | Wells Fargo | Initiated | — | Overweight |
| Mar 27, 2026 | Wolfe Research | Initiated | — | Outperform |
| Mar 16, 2026 | Jefferies | Downgrade | Buy | Hold |
Included in Plus and up
Sign in to see Analyst trend
Two years of the analyst rating mix and the average price target against the price.
